Clinical Trial Update: CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating a CD19 CAR-T cell therapy for treating B-cell malignancies, including acute lymphoblastic leukemia and B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Lymphoma

Drugs mentioned

• CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy (CD19 CAR-T)

Snippet

Sponsor: Wuhan Sian Medical Technology Co., Ltd | Conditions: Acute Lymphoblastic Leukemia, B Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN